In July 2021, US president Joe Biden signed an executive order to promote competition in the American economy, including proposals to tackle a lack of competition in healthcare by increasing support for generic and biosimilar drugs. Nearly a year on, Biosimilars Forum executive director Julie Reed has called for further action from the US Department of Health and Human Services regarding this order, ahead of the launch of numerous Humira (adalimumab) biosimilars in the US market over 2023.
“We encourage the secretary and all of his staff in the administration to do more,” Reed told Generics Bulletin. “We’d like to see more action on the president’s executive order from last year. Their own inspector general’s office has told them they could do more, and we want HHS to prepare for the launches next year
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?